Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Hooks, Shelley B ^a   Callihan, Phillip ^a   Altman, Molly K ^a   Hurst, Jillian H ^a   Ali, Mourad W ^a   Murph, Mandi M ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; LYSOPHOSPHATIDIC ACID; PHOSPHATIDYLSERINE; PROTEIN KINASE B; RGS PROTEIN; RGS10 PROTEIN; RGS17 PROTEIN; RGS2 PROTEIN; RGS5 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; LYSOPHOSPHOLIPID; RGS10 PROTEIN, HUMAN; RGS17 PROTEIN, HUMAN; TAXOID;

ARTICLE; ASCITES FLUID; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENCY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; BIOLOGY; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; OVARY TUMOR; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; RGS PROTEINS; SIGNAL TRANSDUCTION; TAXOIDS; VINCRISTINE;

EID: 77958549663     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-289     Document Type: Article

References (43)

1. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009, 9:415-428. 10.1038/nrc2644, 2814299, 19461667.
2. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003, 3:582-591. 10.1038/nrc1143, 12894246.
3. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008, 100:1630-1642. 10.1093/jnci/djn378, 2720766, 19001604.
4. Mills GB, May C, McGill M, Roifman CM, Mellors A. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 1988, 48:1066-1071.
5. Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 1990, 86:851-855. 10.1172/JCI114784, 296802, 2394835.
6. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, Hurteau J, Casey G, Goodbody A, Mellors A, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995, 1:1223-1232.
7. Xu Y, Fang XJ, Casey G, Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 1995, 309(Pt 3):933-940. 1135721, 7639713.
8. Hurst JH, Hooks SB. Lysophosphatidic acid stimulates cell growth by different mechanisms in SKOV-3 and Caov-3 ovarian cancer cells: distinct roles for Gi- and Rho-dependent pathways. Pharmacology 2009, 83:333-347. 10.1159/000217582, 19420982.
9. Berman DM, Gilman AG. Mammalian RGS proteins: barbarians at the gate. J Biol Chem 1998, 273:1269-1272. 10.1074/jbc.273.3.1269, 9430654.
10. Hurst JH, Hooks SB. Regulator of G-protein signaling (RGS) proteins in cancer biology. Biochem Pharmacol 2009,
11. Hurst JH, Henkel PA, Brown AL, Hooks SB. Endogenous RGS proteins attenuate Galpha(i)-mediated lysophosphatidic acid signaling pathways in ovarian cancer cells. Cell Signal 2008, 20:381-389. 10.1016/j.cellsig.2007.10.026, 18083345.
12. Hurst JH, Mendpara N, Hooks SB. Regulator of G-protein signalling expression and function in ovarian cancer cell lines. Cellular & Molecular Biology Letters 2009, 14:153-174.
13. Rhodes DR. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6. 1635162, 15068665.
14. Kamat AA, Kim TJ, Landen CN, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Research 2007, 67:281-288. 10.1158/0008-5472.CAN-06-3282, 17210709.
15. Buys TP, Chari R, Lee EH, Zhang M, MacAulay C, Lam S, Lam WL, Ling V. Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells. Genes Chromosomes Cancer 2007, 46:1069-1079. 10.1002/gcc.20492, 17726699.
16. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S, Nephew KP. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009, 2:34. 10.1186/1755-8794-2-34, 2712480, 19505326.
17. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95:14863-14868. 10.1073/pnas.95.25.14863, 24541, 9843981.
18. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, et al. Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One 2009, 4:e5583. 10.1371/journal.pone.0005583, 2679144, 19440550.
19. Hasegawa Y, Murph M, Yu S, Tigyi G, Mills GB. Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells. Mol Oncol 2008, 2:54-69. 10.1016/j.molonc.2008.03.009, 2597858, 19081821.
20. Kinsey GR, Blum JL, Covington MD, Cummings BS, McHowat J, Schnellmann RG. Decreased iPLA2gamma expression induces lipid peroxidation and cell death and sensitizes cells to oxidant-induced apoptosis. J Lipid Res 2008, 49:1477-1487. 10.1194/jlr.M800030-JLR200, 2431104, 18398221.
21. Murph M, Mills GB. Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev Mol Med 2007, 9:1-18. 10.1017/S1462399407000476, 17935635.
22. Heximer SP, Watson N, Linder ME, Blumer KJ, Hepler JR. RGS2/G0S8 is a selective inhibitor of Gqalpha function. Proc Natl Acad Sci USA 1997, 94:14389-14393. 10.1073/pnas.94.26.14389, 24991, 9405622.
23. Hunt TW, Fields TA, Casey PJ, Peralta EG. RGS10 is a selective activator of G alpha i GTPase activity. Nature 1996, 383:175-177. 10.1038/383175a0, 8774883.
24. Mao H, Zhao Q, Daigle M, Ghahremani MH, Chidiac P, Albert PR. RGS17/RGSZ2, a novel regulator of Gi/o, Gz, and Gq signaling. The Journal Of Biological Chemistry 2004, 279:26314-26322. 10.1074/jbc.M401800200, 15096504.
25. Fang X, Yu S, LaPushin R, Lu Y, Furui T, Penn LZ, Stokoe D, Erickson JR, Bast RC, Mills GB. Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J 2000, 352(Pt 1):135-143. 10.1042/0264-6021:3520135, 1221440, 11062066.
26. Radeff-Huang J, Seasholtz TM, Matteo RG, Brown JH. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 2004, 92:949-966. 10.1002/jcb.20094, 15258918.
27. Long J, Darroch P, Wan KF, Kong KC, Ktistakis N, Pyne NJ, Pyne S. Regulation of cell survival by lipid phosphate phosphatases involves the modulation of intracellular phosphatidic acid and sphingosine 1-phosphate pools. Biochem J 2005, 391:25-32. 10.1042/BJ20050342, 1237135, 15960610.
28. Mao H, Zhao Q, Daigle M, Ghahremani MH, Chidiac P, Albert PR. RGS17/RGSZ2, a novel regulator of Gi/o, Gz, and Gq signaling. J Biol Chem 2004, 279:26314-26322. 10.1074/jbc.M401800200, 15096504.
29. Chidiac P, Roy AA. Activity, regulation, and intracellular localization of RGS proteins. Receptors Channels 2003, 9:135-147. 10.1080/10606820308241, 12775336.
30. Hollinger S, Hepler JR. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 2002, 54:527-559. 10.1124/pr.54.3.527, 12223533.
31. Posner BA, Mukhopadhyay S, Tesmer JJ, Gilman AG, Ross EM. Modulation of the affinity and selectivity of RGS protein interaction with G alpha subunits by a conserved asparagine/serine residue. Biochemistry 1999, 38:7773-7779. 10.1021/bi9906367, 10387017.
32. Chen CK, Burns ME, He W, Wensel TG, Baylor DA, Simon MI. Slowed recovery of rod photoresponse in mice lacking the GTPase accelerating protein RGS9-1. Nature 2000, 403:557-560. 10.1038/35000601, 10676965.
33. Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N, Oliveira-dos-Santos A, Penninger JM, Muslin AJ, Steinberg TH, et al. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest 2003, 111:1259. 10.1172/JCI200318099C, 152949, 12697745.
34. Nunn C, Mao H, Chidiac P, Albert PR. RGS17/RGSZ2 and the RZ/A family of regulators of G-protein signaling. Semin Cell Dev Biol 2006, 17:390-399. 10.1016/j.semcdb.2006.04.001, 16765607.
35. You M, Wang D, Liu P, Vikis H, James M, Lu Y, Wang Y, Wang M, Chen Q, Jia D, et al. Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research 2009, 15:2666-2674. 2746091, 19351763.
36. Liu P, Vikis HG, Lu Y, Wang Y, Schwartz AG, Pinney SM, Yang P, de Andrade M, Gazdar A, Gaba C, et al. Cumulative effect of multiple loci on genetic susceptibility to familial lung cancer. Cancer Epidemiology, Biomarkers & Prevention: A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology 19:517-524.
37. Stanwood GD, Parlaman JP, Levitt P. Genetic or pharmacological inactivation of the dopamine D1 receptor differentially alters the expression of regulator of G-protein signalling (Rgs) transcripts. Eur J Neurosci 2006, 24:806-818. 10.1111/j.1460-9568.2006.04970.x, 16930410.
38. James MA, Lu Y, Liu Y, Vikis HG, You M. RGS17, an overexpressed gene in human lung and prostate cancer, induces tumor cell proliferation through the cyclic AMP-PKA-CREB pathway. Cancer Res 2009, 69:2108-2116. 10.1158/0008-5472.CAN-08-3495, 2746047, 19244110.
39. Lu J, Gosslau A, Liu AY, Chen KY. PCR differential display-based identification of regulator of G protein signaling 10 as the target gene in human colon cancer cells induced by black tea polyphenol theaflavin monogallate. European Journal Of Pharmacology 2008, 601:66-72. 10.1016/j.ejphar.2008.10.044, 18992738.
40. Cao X, Qin J, Xie Y, Khan O, Dowd F, Scofield M, Lin MF, Tu Y. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene 2006, 25:3719-3734. 10.1038/sj.onc.1209408, 16449965.
41. Bagnato A, Spinella F, Rosano L. Emerging role of the endothelin axis in ovarian tumor progression. Endocrine-Related Cancer 2005, 12:761-772. 10.1677/erc.1.01077, 16322321.
42. Symowicz J, Adley BP, Woo MM, Auersperg N, Hudson LG, Stack MS. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res 2005, 65:2234-2242. 10.1158/0008.5472.CAN-04-2781, 15781636.
43. Shen X, Wang S, Wang H, Liang M, Xiao L, Wang Z. The role of SDF-1/CXCR4 axis in ovarian cancer metastasis. Journal Of Huazhong University Of Science And Technology Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao Yixue Yingdewen Ban 2009, 29:363-367.